{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-058512","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2026-08-24T11:00:37+00:00","discovered_at":"2026-08-24T11:05:03.851800+00:00","generated_at":"2026-08-24T11:05:43.615280+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Precision BioSciences doses first patient in Phase 1/2 FUNCTION-DMD gene editing trial","bullets":["First patient dosed with PBGENE-DMD, first clinical gene-editing program for DMD, at Arkansas Children's Hospital.","PBGENE-DMD excises exons 45-55 to restore near full-length dystrophin; applicable to up to 60% of DMD patients.","Trial enrolling ambulatory DMD patients aged 2-7 with mutations between exons 45-55; initial safety data expected by year-end 2026.","PBGENE-DMD is wholly owned in vivo program using ARCUS platform; aims to durably improve function."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-058512","json":"https://secwatch.observer/filing/0001628280-26-058512.json","markdown":"https://secwatch.observer/filing/0001628280-26-058512.md","text":"https://secwatch.observer/filing/0001628280-26-058512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/0001628280-26-058512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/dtil-20260824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-24T11:05:43.615280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}